This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Herbert D. Kleber, MD; Myrna M. Weissman, PhD; Bruce J. Rounsaville, MD; Charles H. Wilber, EdM; Brigitte A. Prusoff, PhD; Charles E. Riordan, MD

Arch Gen Psychiatry. 1983;40(6):649-653.

Abstract
• This report describes the results of a placebo-controlled double-blind clinical trial evaluating imipramine hydrochloride, a tricylic antidepressant, as treatment for depression in methadone-maintained opiate addicts. Forty-six subjects were assigned randomly to either the imipramine or placebo group for up to eight weeks. All patients also received mandatory once weekly group therapy as part of the methadone program. Outcome measures included attrition, depressive symptoms, global improvement, side effects, social functioning, and urine specimen results positive for illicit drugs. The therapeutic response in the two conditions was similar. Addicts receiving either imipramine or placebo experienced a substantial reduction of depressive symptoms during the eight weeks of the study. These findings are compared with other studies that treat depression in addicts and nonaddicts.

(Arch Gen Psychiatry 1983;40:649-653)

Author Affiliations
From the Departments of Psychiatry (Drs Kleber, Weissman, Rounsaville, Prusoff, and Riordan) and Epidemiology (Dr Weissman), Yale University School of Medicine, New Haven, Conn, and Connecticut Mental Health Center, New Haven (Drs Kleber, Weissman, Rounsaville, Prusoff, Riordan, and Mr Wilber).

Footnotes
Accepted for publication Aug 10, 1982.

Reprint requests to 34 Park St, New Haven, CT 06508 (Dr Kleber).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology
Lingford-Hughes et al.
J Psychopharmacol 2004;18:293-335.
 

Treatment of Depression in Patients With Alcohol or Other Drug Dependence: A Meta-analysis
Nunes and Levin
JAMA 2004;291:1887-1896.
ABSTRACT | FULL TEXT  

Pharmacotherapy Plus Psychotherapy for Treatment of Depression in Active Injection Drug Users
Stein et al.
Arch Gen Psychiatry 2004;61:152-159.
ABSTRACT | FULL TEXT  

A Reevaluation of the Exclusion Criteria Used in Antidepressant Efficacy Trials
Posternak et al.
Am. J. Psychiatry 2002;159:191-200.
ABSTRACT | FULL TEXT  

Imipramine Treatment of Opiate-Dependent Patients With Depressive Disorders: A Placebo-Controlled Trial
Nunes et al.
Arch Gen Psychiatry 1998;55:153-160.
ABSTRACT | FULL TEXT  

A 2.5-Year Follow-up of Cocaine Use Among Treated Opioid Addicts: Have Our Treatments Helped?
Kosten et al.
Arch Gen Psychiatry 1987;44:281-284.
ABSTRACT  

Prognostic Significance of Psychopathology in Treated Opiate Addicts: A 2.5-Year Follow-up Study
Rounsaville et al.
Arch Gen Psychiatry 1986;43:739-745.
ABSTRACT